<h5>Tasty beer starts with knowing what’s in your hops. Explore how online SPE makes bitter acid analysis in hops faster and more reliable.</h5><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_326238593f.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_326238593f.jpeg 245w," sizes="100vw" width="1024" height="512"><h3>How can you detect bitter acid profiles quickly, reliably, and more sustainably?</h3>For craft brewers and beer lovers alike, a refreshing experience is all about flavor.So how can you achieve the desired bitterness in your beer? The answer is not just about the recipe. Finding the right flavor profile starts with the bitter acids present in the starting hops material.<div><div>Hops (the heart of your favorite beer) are the source of the brew’s distinctive flavor tied to bitterness and aroma.At the molecular level, bitterness is driven by <a target="_blank" rel="noopener noreferrer" href="https://www.sciencedirect.com/science/article/pii/S0308814622016338">α- and β-bitter acids</a>, like humulones and lupulones, whose concentrations determine the final sensory profile of the beer (Figure 1).Accurately characterizing these compounds in each batch allows brewers to unlock the full potential of every variety of hops.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_2_6435757c03.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 1. General chemical structure of hop bitter acids." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_2_6435757c03.jpeg 222w," sizes="100vw" width="700" height="493">While conventional analytical methods rely on long, manual sample preparation steps and hazardous solvents, laboratories now strive for greener and more efficient workflows.And moving from manual to online sample preparation is one of the easiest ways your lab can reduce waste and — most importantly — improve reliability with automation.<h3>Key takeaways</h3><ul><li>Online SPE reduces hands-on work, shortens turnaround time, and supports more sustainable methods by cutting solvent use and eliminating single-use cartridges.</li><li>Automated UHPLC workflows are easier for new users to execute, offering more reproducible quantifications of α- and β-bitter acids in hops.</li><li>Accurate bitter acid profiles help brewers distinguish hop varieties and control flavor with confidence.</li></ul><h3>Comparing offline vs. online solid phase extraction for bitter acid HPLC analysis</h3>If you’ve spent long hours in the lab preparing samples for hops analysis, you’re not alone.Manual sample preparation often takes the most time in hops analysis, an area where online <a target="_blank" rel="noopener noreferrer" href="https://www.thermofisher.com/content/lifetech/global/en/home/industrial/chromatography/chromatography-learning-center/chromatography-consumables/sample-prep.html">solid phase extraction</a> (SPE) can make a real difference. Here’s why.Manual SPE has a lot of manual steps. Extraction. Cartridge loading. Washing. Elution. And sometimes solvent exchange or reduction. All before your actual analysis begins. This labor-intensive workflow can take up to an hour and depends strongly on operator skillsets, making reproducibility a challenge for new hires.<h3>Online SPE analysis provides key benefits like:</h3><ul><li>Hands-off workflow free of cartridges, manifolds, or vacuum steps.</li><li>Column washing and re-equilibration occur in parallel with separation.</li><li>SPE step is complete in just two minutes.</li><li>Minimizes operator-dependent variability.</li><li>Uses less than 8 mL of solvent.</li></ul>Let’s explore what this technique looks like in practice.<h3>Online SPE for analyzing α- and β-bitter acids in hops standard solutions.</h3>Changing your sample preparation from manual to automated isn’t complicated. With the right tools you can fully integrate online SPE with your UHPLC system (Figure 2).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_3_4fb14243b4.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 2. Schematic workflow for the determination of bitter acids in hops. The process involves clean up and instrumental analysis using the Thermo Scientific Vanquish Online SPE UHPLC System." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_3_4fb14243b4.jpeg 245w," sizes="100vw" width="700" height="323"><h3>The process for analyzing a hops standard solution is straightforward:</h3><ol><li>First, extract hop samples with ethanol (a greener alternative to toluene or diethyl ether in conventional methods).</li><li>Inject the extract directly into your instrument for analysis. Bitter acids retain<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1970"> on the SPE column</a> while matrix interferences that can comprise quantitation are removed.</li><li>Next, backflush the SPE column to transfer the analytes to the<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/423"> analytical column </a>for separation. While this separation is taking place, the SPE column is washed and re-equilibrated in parallel, keeping the total run time to 15 minutes, with the separation of all six major bitter acids in a single analysis (Figure 3).</li></ol><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_4_1e47405e3c.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 3. UV chromatogram of hop bitter acids in standard solution (1-cohumulone, 2-humulone, 3-adhumulone, 4-colupulone, 5-lupulone, 6-adlupulone)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_4_1e47405e3c.jpeg 245w," sizes="100vw" width="700" height="347"><h3>Online SPE for analyzing α- and β-bitter acids in real hops samples</h3>Analytical labs need methods that are accurate and reliable for brewers to develop distinct and reproducible flavor profiles across batches.To assess the applicability of online SPE UHPLC methods for hops analysis, we analyzed bitter acid profiles from four species — Sultana, Barbe Rouge, Azacca, and Sabro.The concentration of α-acids dominated all samples, while each hops species exhibited distinct profiles in terms of α-acid and β-acid content, making them suitable for different brewing strategies (Figure 4).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_5_3a179217db.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 4. Bitter acid profiles in four different hop species, error bars display SD (n=6). To check method consistency, we measured each hops extract six times. Variation between measurements was low, with relative standard deviation below 3.5 % across all hops species." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_5_3a179217db.jpeg 245w," sizes="100vw" width="700" height="410"><ul><li>For testing labs, this process translates into a workflow that is easy to run, fast, and delivers reliable results without added complexity.</li><li>For craft brewers, reliability means clear, trustworthy insights into hops bitter acid profiles, for better hop selection and more precise control of bitterness and flavor in your beer.</li></ul><h3>From carefully procured samples to tasty sips</h3>Efficient UHPLC workflows support faster results, less solvent use, and reliable bitterness data for brewers. And online SPE turns those advantages into practical, day-to-day benefits for brewers and labs alike.<ul><li>Less hands-on skills required for lab analysts</li><li>Faster results from labs to brewers</li><li>A more sustainable way to work</li><li>Clear insights into hops flavor</li></ul>To learn more about the method and see the full application data, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/cn_004238_hplc_vanquish_online_spe_bitter_acids_hops_cn004238_na_en_587a5d300b.pdf">check out our application note today</a>.<h3>FAQs</h3><div><div><h5>What are the key compounds in hops analyzed by HPLC?</h5>Bitter acids, namely α-acids and β-acids, especially the six major bitter acids (humulones and lupulones) that define hop bitterness and are required for quality control and brewing decisions.</div><div><h5>What column types are recommended for hop acid separations?</h5>Classical C18 Silica columns are ideal for bitter acids separation. UHPLC compatible columns with particle size ≤ 2 µm boost analysis with higher flow rate, thus shorter analysis time and solvent consumption.</div><div><h5>What’s the best workflow for hops analysis?</h5>A typical workflow for hop analysis consists of three main steps: extraction of the target compounds, clean-up of co-extracted matrix components, and instrumental analysis by HPLC or UHPLC. To keep this workflow efficient and reproducible, you should minimize manual handling and add in automation when possible. Integrating online SPE into your LC instrument allows sample clean-up to run automatically, reducing hands-on time, solvent use, and variability while delivering faster, more reliable results.</div></div><blockquote>Visit us on&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/showcase/72003132/admin/dashboard/">LinkedIn:</a>&nbsp;#UHPLC #Automation</blockquote></div></div>

How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors

In the week of June 29, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars">👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</a></h4>👉 Search and filter in the largest global database with over 5 500 GC, LC, MS and spectroscopy webinars.</blockquote><h5>1. Thermo Fisher Scientific: Insights from an IC specialist: To be suppressed or not suppressed?</h5><ul><li>Tu, 30.6.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6310">Registration</a></li></ul>Join Thermo Fisher’s Ask the Experts session to learn how suppressor technology impacts ion chromatography performance, sensitivity, reliability, maintenance, and troubleshooting.<h5>2. SCIEX: Advancing Proteomics with ZenoTOF: From Single-Cell Analysis to Plasma Biomarker Discovery</h5><ul><li>Tu, 30.6.2026 11:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6311">Registration</a></li></ul>Discover how ZenoTOF high-resolution mass spectrometry is accelerating single-cell proteomics and plasma biomarker discovery through enhanced sensitivity, throughput, and automation.<h5>3. Agilent Technologies: Measuring Diverse Samples with UV/VIS Spectrometers and Integrating Spheres</h5><ul><li>Tu, 30.6.2026 20:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6052">Registration</a></li></ul>This webinar will discuss diffuse transmission and reflection UV/VIS measurements, including how to perform measurements with Agilent’s Cary 60 UV/VIS Spectrometer.<h5>4. Waters Corporation: Informatics series #33 Tips, Tricks and Best Practices</h5><ul><li>Th, 2.7.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6315">Registration</a></li></ul>This interactive session revisits essential features, shortcuts, and practical techniques in Empower software that can streamline everyday laboratory work and reduce unnecessary effort.<h5>5. Waters Corporation: Unlocking Therapeutic Peptide Characterisation (GLP-1RAs) with Cyclic IMS</h5><ul><li>Th, 2.7.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6313">Registration</a></li></ul>Discover how cyclic ion mobility spectrometry (cyclic IMS) improves characterization of GLP-1 analogues and therapeutic peptides, supporting development, quality control, and regulatory submissions.<h5>6. Agilent Technologies: Spectral Flow Cytometry Masterclass - Session 1</h5><ul><li>Fr, 3.7.2026 07:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6316">Registration</a></li></ul>Learn how full-spectrum flow cytometry enables high-dimensional cell analysis. Explore spectral flow technology, experimental design, and applications in immunology, oncology, and vaccine research.

Webinars LabRulezLCMS Week 27/2026

The international standard ISO/IEC 17025 [1] clause 7.7.2 with regards to ensuring the validity of results, requires a laboratory to participate in proficiency testing (PT) and/or to participate in interlaboratory comparisons (ILCs) other than PT. However, no guidance as to what these other ILCs might be, or indeed how they might compare in relation to PT, is provided. This leaflet aims to outline other ILCs available, pointing out some of the limitations as compared to PT.&nbsp;There are three major types of ILCs in which a group of laboratories analyses identical portions from a homogeneous, stable test sample, with each type being characterized by its intended purpose [2,3]:<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_2_d9263807fb.jpg" alt="Eurachem: Interlaboratory comparisons other than proficiency testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_2_d9263807fb.jpg 245w," sizes="100vw" width="1507" height="607">A key point is that PT is an ILC that is designed to specifically evaluate the performance of participants, providing them with an infrastructure to monitor and assess the validity of their results. This is not the key purpose of the two other ILCs, and thus depending on their intended purpose they have a number of limitations that laboratories need to be aware of when using them rather than PT. Only proficiency testing should have been conducted in full compliance to the competency standard ISO/IEC 17043 [4].&nbsp;<h4>Evaluation of measurement procedure performance&nbsp;</h4>These ILCs, are designed to assess how a particular measurement procedure performs and whether it is fit for its intended purpose. These ILCs are often referred to as a ‘method performance study’ or a ‘collaborative study’ [2]. Some limitations of using such ILCs for monitoring laboratory performance as an alternative to PT are:&nbsp;<ul><li>All participants use the same measurement procedure i.e. the measurement procedure that is being validated. Unless the measurement procedure is being routinely used by the participating laboratory such an ILC will not assess the routine performance of the laboratory using their own routine measurement procedure. Nor does it enable them to compare their performance with other laboratories using alternative measurement procedures.&nbsp;</li><li>The measurement procedure is likely to be new, so participants may not have established stable procedures and quality control, so performance may not reflect routine use.&nbsp;</li><li>The report from such an ILC would not provide information on the performance of the participant, if the statistical model used makes the assumption that all laboratories perform with equal variability.</li><li>The design of the study may require the participants to assess multiple samples and/or to undertake multiple replicate analysis on the test materials. This may not be representative of the routine measurements or tests undertaken by the laboratory.&nbsp;</li><li>The conclusion of the ILC might be that the measurement procedure being assessed is not valid.&nbsp;</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_3_a53ecd2f5d.jpg" alt="Eurachem: Interlaboratory comparisons other than proficiency testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_3_a53ecd2f5d.jpg 157w," sizes="100vw" width="570" height="566"><h4>Characterisation of candidate reference materials&nbsp;</h4>These are ILCs that assign a property value to a candidate reference material, usually with a stated measurement uncertainty. These are often referred to as a ‘material certification study’ [2]. Limitations of using such ILCs as an alternative to PT are:&nbsp;<ul><li>The analysis of the candidate reference material is likely to require additional care in exercising the routine measurement procedure, such as substantially more replication, and/or may require quite different reporting formats (e.g. all valid replicates instead of a mean result). Thus, such an ILC will not necessarily provide an evaluation of the performance of the laboratory based on the routine use of their measurement procedures.&nbsp;</li><li>The report from such an ILC may include the results from the participating laboratories but would not provide information on the performance of each laboratory.&nbsp;</li><li>Participating laboratories may be required to assess multiple samples and/or to undertake multiple replicate analysis on the candidate reference materials. Thus this may not be representative of the routine measurements or tests undertaken by the laboratory.&nbsp;</li></ul><h4>Other ILCs&nbsp;</h4>Some other ILCs, whilst not being conducted in full compliance of the requirements of ISO/IEC 17043, may be designed to evaluate participant performance. These would include small ILCs as defined by EA‑2/21 [5] or split sample ILCs i.e. where a portion of a single sample is sent to two or three laboratories. Whilst these ILCs are specifically designed to evaluate participant performance, they may not provide a comprehensive comparison that a PT might provide. In such cases the laboratory needs to evaluate carefully the competence of the organization managing the ILC and the suitability of the service externally provided (ISO/IEC 17025 clause 6.6).

Interlaboratory comparisons other than proficiency testing

Article

Webinars

Academy

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

Eurachem is a European network promoting international traceability of chemical measurements and good analytical practice. It provides expert guidance, supports method validation, uncertainty evaluation, proficiency testing, and facilitates discussion on technical and policy issues in analytical quality.

Eurachem

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Agilent Technologies

SelectScience

The meeting will dive into the topic of Dissolution Testing of semisolid formulations and spotlight on the most relevant instruments/accessories available. We will also discuss some tips and tricks for the method development of semisolids.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Agilent Technologies: Revisions to USP chapter 1724 - Dissolution Testing of Semisolids

Revisions to USP chapter 1724 - Dissolution Testing of Semisolids

Join us to get an update on the latest changes and additions to USP chapter <1724>.

Rev. to USP chapter 1724 - Dissolution Testing of Semisolids

Join the DDG expert panel for an update on the Key Regulatory and Compendial Dissolution Updates from 2021. With our busy lives it is always difficult to find time to scan all the regulatory bodies for news, so this a great opportunity to get yourself up-to-date on the regulatory topic. Bryan Crist, our panel member, brings many years of experience working on various USP committees to this meeting and supports the discussion of the latest updates and what they mean for your day-to-day work.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Agilent Technologies: What You (May) Have Missed: Key Regulatory and Compendial Dissolution Updates in 2021

What You (May) Have Missed: Key Regulatory and Compendial Dissolution Updates in 2021

Join the DDG expert panel for an update on the Key Regulatory and Compendial Dissolution Updates from 2021.

Key Regulatory and Compendial Dissolution Updates in 2021

Lipid nanoparticles, nanospheres, nanocrystals, liposomes, dendrimers, Iscoms…what are all these different particles? What do they have in common? What makes them so attractive for the delivery of drugs, as parenteral delivery systems and especially for the delivery of vaccines? Why are dissolution studies so challenging with these particulate carriers? Let’s take a closer look at all these questions and try to answer them with our group of experts from the DDG panel and industry experts.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Exploring Dissolution Techniques for Vaccines, Liposomes, and Parenterals

Let’s take a closer look at all these questions and try to answer them with our group of experts from the DDG panel and industry experts.

Dissolution for Vaccines, Liposomes, and Parenterals

While solid dosage forms like tablets are still the widely used option for the delivery of medication, there is an increasing need for alternative dosage forms. Medical devices are on the rise and when combined with a drug, they most likely also need to undergo dissolution testing, which can be challenging with the conventional apparatus. Many novel dosage forms, e.g. electro spun fleeces, microneedle patches, implants also require modifications to the dissolution apparatus we know. Join us for a discussions on these challenges and how they can be overcome.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Agilent Technologies: Current Practices for the Dissolution Testing of Medical Devices, Combination Products, and Novel Dosage Forms

Current Practices for the Dissolution Testing of Medical Devices, Combination Products, and Novel Dosage Forms

Join us for a discussions on challenges and how they can be overcome.

Practices for the Dissolution Testing of Medical Devices

Development of veterinary products is a challenge in itself. Animal ranges from very small to very large, so how to accommodate the large dosage range? Special flavors need to be added. What dosage forms are accepted by animals? Thinking about this, you can imagine, that dissolution testing of these products can present a real challenge. Let’s take a trip to the vet and explore our options.
<blockquote>
Presenter: Karen Krauel-Göllner, PhD (Product Manager Dissolution, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Karen Krauel-Göllner is a registered pharmacist and holds a PhD in Pharmacy from the University of Otago, New Zealand. Karen has worked in various roles in the field of pharmaceutical development. For the last 5 years she has been working with Agilent Technologies and currently holds a position as product manager for dissolution systems.
</blockquote>
<blockquote>
Presenter: Ken Boda (Dissolution Product Specialist, Agilent Technologies, Inc.)
</blockquote>
<blockquote>
Ken joined Varian (now Agilent) in 2005 as an Applications Engineer and is now a Dissolution Product Specialist. Prior to working at Agilent, he worked in pharma specializing in dissolution testing and method development. As a Dissolution Product Specialist, Ken works with customers in determining the best systems for their needs and optimizing their work flows. He has also helped educate customers on dissolution science through webinars, the Dissolution Discussion Group, LinkedIn, and other channels.
</blockquote>
<blockquote>
Presenter: Bryan Crist (President, DissoAssist Consulting)
</blockquote>
<blockquote>
Bryan is currently the president of DissoAssist consulting based in Wilmington, NC since 2021. He provides consulting, coaching, and training services for dissolution and drug release in the pharmaceutical industry, specifically, the areas of product and method development and validation, technology transfer, regulatory and compendial compliance, automation, troubleshooting, aberrant data investigation, apparatus and instrument qualification, SOP development, and laboratory audits.
</blockquote>
<blockquote>
Previously, Bryan was a Scientific Affairs Manager with Agilent Technologies located in Cary, North Carolina, USA. His activities from 1997 until 2021 had focused on providing method and technical application support for dissolution and drug release testing in the pharmaceutical industry as well as working with VanKel, Varian and eventually Agilent R&amp;D, Marketing and Sales teams. Prior to 1997, Bryan performed analytical testing, supervised, and managed pharmaceutical laboratories with Bristol-Myers Squibb, Merck, AAI and Abbott Laboratories until he joined the dissolution equipment manufacturer VanKel.
</blockquote>
<blockquote>
Bryan has developed and routinely conducts numerous seminars related to dissolution and drug release testing. He’s provided numerous talks at exhibitions and conferences and has published numerous articles in journals and book chapters on dissolution related techniques and topics. He received his B.S. degree in Chemistry from Atlantic Christian College in Wilson, North Carolina. Bryan has been a former member of the USP Biopharmaceutics Expert Committee and is presently a member of several USP Expert Panels on Performance Verification Testing, Capsules, Performance Tests for Semisolid Dosage Forms and Solubility Criteria for Veterinary Drugs. He’s a Steering Committee member of the AAPS In-Vitro Release Dissolution Testing (IVRDT) Community Leadership Team, co-founder and co-moderator of the Dissolution Discussion Group (DDG) and is a current member of the American Chemical Society.
</blockquote>
<blockquote>
Presenter: Vivian Gray (Founder VA Gray Consulting; Managing Director of Dissolution Technologies)
</blockquote>
<blockquote>
Vivian has spent the last 40+ years involved in all aspects of dissolution testing and evaluating new dissolution technology. At the United States Pharmacopeia, she enjoyed a long career serving first as a bench chemist, supervisor and lastly as a liaison to various expert USP committees, including the Biopharmaceutics and Dissolution Expert Committee. In 1997, Vivian joined the DuPont-Merck Pharmaceuticals Company Analytical Research and Development Section as the Head of the Dissolution Group.
</blockquote>
<blockquote>
Vivian has been an invited speaker for conferences on 70 occasions (28 of these were international invitations), lecturing especially in the areas of dissolution method development and validation, FDA requirements in dissolution testing, troubleshooting dissolution method problems, and new dissolution technology and dosage forms. She is a proactive participant in the field as demonstrated by 54 publications, including 6 book chapters. Vivian has co-authored a book on dissolution testing called “Handbook of Dissolution Testing”, Third Edition, published in 2004.
</blockquote>

Agilent Technologies: A Trip to the Vet: Expert Advice about Dissolution Testing of Veterinary Products

A Trip to the Vet: Expert Advice about Dissolution Testing of Veterinary Products

Let’s take a trip to the vet and explore our options.

Advice about Dissolution Testing of Veterinary Products

Novel dosage forms require novel dissolution techniques and instruments. Drug-eluting stent testing, transdermals, implants, contact lenses, medical devices, and a variety of other products require absolute control over evaporative losses and assurance of analytical sample integrity. The dissolution testing is frequently done using ultralow volumes in the 5–10 mL range.
In this webinar, we will explore tools and techniques that address the challenges of these types of analysis by examining several examples and case studies.
<h5>Key learning objectives</h5>
<ul>
<li>Discover dissolution techniques for novel formulations</li>
<li>Explore case studies for small-volume dissolution testing</li>
<li>Learn about the Agilent 400-DS</li>
</ul>
<h5>Who should attend?</h5>
<ul>
<li>Dissolution users, lab managers in R&amp;D and QC, and drug/device manufacturers</li>
</ul>
<blockquote>
Presenter: Dr. Karen Krauel-Goellner (Product Manager Dissolution Systems, Agilent Technologies)
</blockquote>
<blockquote>
Dr. Karen Krauel-Goellner is a registered pharmacist and holds a PhD from the University of Otago, NZ, in the area of formulation development. Krauel-Goellner previously held research positions at universities and Boehringer Ingelheim, and worked as a clinical supply manager at Boehringer Ingelheim Vetmedica. In 2013, Krauel-Goellner joined Agilent Technologies and is currently a Global Product Manager for Agilent Dissolution Systems. 
</blockquote>
<blockquote>
Presenter: Georgina Wynne Hughes (Editorial Team, SelectScience)
</blockquote>
<blockquote>
Georgina studied at Birmingham University where she gained a BSc in Biomedical Science, and an MSc by Research in Cancer and Genomic Sciences, which focused on defective autophagy in rare neurodegenerative diseases. As a member of the Editorial team, she now plays an integral role in shaping the content on SelectScience.
</blockquote>

Select Science: Overcoming Dissolution Challenges with Low-Dose Pharmaceuticals and Medical Devices

Overcoming Dissolution Challenges with Low-Dose Pharmaceuticals and Medical Devices

We will explore tools and techniques that address the challenges of these types of analysis by examining several examples and case studies.

LCMS webinars focusing on Dissolution - page 3